ARTL

Artelo Biosciences operates as a clinical-stage biopharmaceutical company developing cannabinoid-based therapies for diseases with significant unmet medical needs including pain, inflammation, and cancer-related conditions. Headquartered in Solana Beach, California, the company focuses on synthetic cannabinoid compounds and endocannabinoid system modulators designed to harness therapeutic benefits of cannabis-derived molecules while avoiding psychoactive effects associated with THC. Artelo's lead drug candidate, ART27.13, represents a synthetic dual FAAH/MAGL inhibitor in clinical development for treating cancer-related anorexia-cachexia syndrome, a devastating condition causing severe weight loss and muscle wasting in cancer patients with no approved effective treatments. The company's pipeline includes ART26.12, a peripherally-restricted CB1 agonist for inflammatory bowel disease and other gastrointestinal conditions, and ART12.11, a synthetic cannabidiol derivative for inflammatory and neurological disorders. Artelo's research strategy emphasizes developing highly selective cannabinoid compounds targeting specific receptors and enzymes within the endocannabinoid system, potentially offering improved efficacy and reduced side effects compared to natural cannabis extracts. The company operates with a capital-efficient model using contract research organizations for clinical trials and manufacturing rather than maintaining internal facilities. Artelo collaborates with academic institutions and research centers conducting preclinical studies exploring additional applications for its proprietary cannabinoid compounds.